VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2019 | MABCUTE: rituximab maintenance in R/R indolent NHL

Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the results of the phase III MABCUTE study (NCT01461928) which investigated the efficacy and safety of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-hodgkin lymphoma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter